Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07205718 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT07205718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07205718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 19, 2025
Completion date
December 21, 2029
Enrollment
273 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors